A 3D View: Personalized Management of Patients with Idiopathic Pulmonary Fibrosis in Clinical Practice: Emphasis on Improving Tolerability and Safety
Gregory Cosgrove, MD, FCCP
Assistant Director, Interstitial Lung Disease Program
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Endowed Chair in Interstitial Lung Disease
National Jewish Health
Sandra G Adams, MD
University of Texas School of Medicine
San Antonio, TX
This 3D, case-based, live activity will cover the diagnosis, treatment, and management of idiopathic pulmonary fibrosis (IPF) in clinical practice.
This activity is designed for US-based academic and community-based pulmonologists, radiologists, and primary care providers; registered nurses; advanced practice nurses; physician assistants; and respiratory therapists who form the multidisciplinary team involved in the management of patients with IPF.
Upon completion of the program, attendees should be able to:
- Describe updated information from the most recent, evidence-based IPF treatment guidelines to enhance treatment tolerability and safety, and improve patient outcomes
- Review the mechanisms of action of agents that target fibroblast accumulation and myofibroblast differentiation in patients with IPF, as well as clinical trial data on their efficacy, tolerability, and safety profiles; and
- Discuss best practices for the provision of interdisciplinary team-based comprehensive care and disease management, with an emphasis on safety and tolerability concerns for patients with IPF, particularly those with comorbid conditions.
ACCREDITATION AND DESIGNATION STATEMENT
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider approved by the California Board of Registered Nursing, Provider Number 12724, for 1.2 contact hours.
DISCLOSURE POLICY STATEMENT
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health is dedicated to providing continuing medical education that is independent, fair, balanced, objective, and free of commercial bias. The Office of Professional Education and the Continuing Medical Education (CME) committee at National Jewish Health require that all scientific session faculty comply with all applicable laws and regulations governing disclosure. All financial interests or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services must be disclosed.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Gregory Cosgrove reports that he has served on advisory boards and as a consultant for Genentech, Boehringer Ingelheim, Global Blood Therapeutics, and Veracyte. He has served as an investigator for Genentech, Boehringer Ingelheim, and Global Blood Therapeutics. In addition, he has received honoraria and grants from Genentech, Boehringer Ingelheim, and Global Blood Therapeutics and honoraria from Veracyte.
Dr. Sandra Adams has received educational grants from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Novartis, and Sunovian.
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
Tristan J. Huie, MD, Clinical Director, Interstitial Lung Disease Program, Department of Medicine for National Jewish Health, has nothing to disclose.
CNE content review
Allidah Poole Hicks, RN, MS, AE-C, Staff Development RN, Department of Nursing for National Jewish Health, has nothing to disclose.
Staff, planners, and managers
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Brooke Hefele, Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Kathleen Krafton, Medical Director, Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group, has nothing to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, Director, Office of Professional Education for National Jewish Health, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
National Jewish Health and Med Learning Group require that faculty participating in any CME/CNE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity;
3. Complete pre-and-post surveys; and
3. Submit the evaluation form to the Med Learning Group.
You will receive your certificate via email within 30 days.
For questions about this activity, please contact: Med Learning Group at email@example.com.
For questions about the CME or CNE certification of this activity, please contact the Office of Professional Education at National Jewish Health at firstname.lastname@example.org.
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course, or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the enduring event at email@example.com
RELEASE DATE: December 19, 2017
EXPIRATION DATE: December 19, 2018
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.